Prof. Dr. med. Peter Fasching

Department of Obstetrics and Gynaecology Professur für Translationale Frauenheilkunde und Geburtshilfe

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence (2026) Khor CC, Ong WS, Lim EH, Chatelut E, Chen S, Muerdter TE, Abraham JE, et al. Journal article PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry (2026) Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer – results from the phase II DETECT IVb trial (2026) Schochter F, Friedl TW, Schäffler H, Meier-Stiegen F, Pfister KN, Riethdorf S, Wiesmüller L, et al. Journal article AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update (2026) Hartkopf A, Albert US, Bartsch R, Bauerfeind I, Banys-Paluchowski M, Bjelic-Radisic V, Blohmer JU, et al. Journal article, Review article Breast cancer prevention in patients with gBRCA-mutated ovarian cancer (2026) Amann N, Krückel A, Brückner L, Gocke J, Müller C, Heindl F, Hack C, et al. Journal article Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (2026) Schmid P, Cortes J, Dent RA, McArthur HL, Pusztai L, Kuemmel S, Denkert C, et al. Journal article The SURVIVE study: Re-evaluating follow-up in early breast cancer. (2026) Huesmann ST, Friedl TW, Pfister K, Schäffler H, Fink A, Braun T, Mehmeti F, et al. Journal article Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort (2026) Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, et al. Journal article